Neloviren (Linagliptin)

Linagliptin, the active ingredient in Neloviren, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adults, helping to improve glycemic control when used with diet and exercise. GNH USA supplies Neloviren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neloviren, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers HbA1c levels and improves overall glycemic control. - Type 2 diabetes mellitus (monotherapy): reduces fasting plasma glucose when diet and exercise are insufficient. - Type 2 diabetes mellitus (add‑on therapy): enhances post‑prandial glucose control when combined with other oral antidiabetics.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Gastrointestinal upset: occasional nausea, abdominal discomfort or diarrhea. - Dizziness: occasional light‑headedness, especially on standing. - Upper respiratory infection: cough or sore throat. - Fatigue: mild tiredness reported by some patients. Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with nausea, requiring immediate medical attention. - Severe hypersensitivity: rash, angioedema or anaphylactic reactions. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: rare autoimmune skin blistering disorder.

Linagliptin should be used with caution in specific clinical situations. - Renal impairment: assess renal function; dose adjustment may be required. - Hepatic disease: monitor liver enzymes regularly. - Cardiovascular disease: use with caution and monitor for any worsening symptoms. - Elderly patients: observe for hypoglycemia when combined with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Linagliptin may interact with several medicines that affect its plasma concentration or glucose‑lowering effect. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin efficacy. Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: heightened risk of hypoglycemia; monitor blood glucose. - Rifampicin: may lower therapeutic effect, requiring glycemic monitoring. - Diuretics: possible alteration of glucose control; observe patient response.